BRIEF-Lantheus Announces Alzheimer’s Disease Radiodiagnostic Mk-6240 Meets Co-Primary Endpoints In Two Pivotal Studies

Reuters
30 Apr
BRIEF-Lantheus Announces Alzheimer’s Disease Radiodiagnostic Mk-6240 Meets Co-Primary Endpoints In Two Pivotal Studies

April 30 (Reuters) - Lantheus Holdings Inc LNTH.O:

  • LANTHEUS ANNOUNCES ALZHEIMER’S DISEASE RADIODIAGNOSTIC MK-6240 MEETS CO-PRIMARY ENDPOINTS IN TWO PIVOTAL STUDIES

  • LANTHEUS HOLDINGS INC - NDA SUBMISSION FOR MK-6240 EXPECTED IN Q3 2025

Source text: ID:nGNXbKRdgR

Further company coverage: LNTH.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10